Ligachembio
Public · 4 known investors
LigaChemBio is a biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) and small molecule therapeutics, with proprietary ADC technology and a drug development pipeline. The page shown is an investor disclosure section listing regulatory filings.
Also known as LCB · LegoChem Biosciences · LigaChem Bio · LigaChem Biosciences · 리가켐바이오
Investors · 4
Also in the syndicate · 3
Company profile
researched Aug 2026LigaChem Biosciences, Inc. (LCB), formerly LegoChem Biosciences, is a clinical-stage biopharmaceutical company headquartered in Daejeon, South Korea. It applies medicinal chemistry expertise to biologics with the aim of making them more targeted and potent, concentrating its R&D on antibody-drug conjugates (ADCs), immuno-oncology drugs and small-molecule therapeutics, including ADC payloads.
The company's pipeline includes LNCB74, a B7-H4-targeting ADC in Phase 1 trials in solid tumors; LCB02A, a Claudin 18.2-targeting ADC for which a global Phase 1/2 IND was approved; LCB71, a ROR1 ADC; and LCB84, a TROP2 ADC licensed to Janssen. It also lists small-molecule programs covering novel-mechanism immuno-oncology agents and cytotoxic payloads.
LigaChem describes a corporate roadmap, "VISION 2030," that moves from early-stage out-licensing at the preclinical/IND stage (through 2023), to clinical development of its own pipeline through Phase 1/2 with bispecific antibodies and novel payloads (through 2027), to late-clinical and commercial-stage development plus royalty streams from partnered programs and ADC applications beyond oncology such as immunotherapy and infectious disease (through 2030). The company also maintains an ESG program.
Founding story
The company was established in 2006 under the name LegoChem Biosciences by founders including Kim Yong-Joo, who serves as CEO, and Park Se-Jin, who serves as president, building the business around medicinal chemistry expertise applied to biologics.
Business model
The company develops proprietary ADC platform technology and drug candidates and monetizes them through global licensing, co-development and research collaborations with pharmaceutical and biotech partners, alongside advancing its own clinical pipeline. Its stated model has evolved from early-stage out-licensing at the preclinical/IND stage toward carrying internal programs through Phase 1/2 and, longer term, into late-clinical and commercial stages with continued royalty revenue from partnered pipelines.
Revenue is generated from out-licensing and technology transfer deals, including upfront and milestone payments and royalties from partnered programs, with commercialization of its own products a stated longer-term objective.
Traction
LigaChem reported that its ROR1 ADC LCB71 achieved 100% objective response and complete response rates in a first-line DLBCL combination trial, based on 31 first-line DLBCL patients per partner-related coverage. A global Phase 1/2 IND for the Claudin 18.2 ADC LCB02A was approved, with global trial entry targeted for the third quarter of 2026, and LNCB74 is in Phase 1 trials in solid tumors. The company won two awards at the World ADC Awards, is eligible for milestone payments from SOTIO Biotech, and reported 418 billion won in cash and cash equivalents as of the end of the first quarter of 2026, rising to roughly the 900 billion won range after a 500 billion won state fund investment.
Latest developments
In June 2026 LigaChem announced 500 billion won of financing from the government-led National Growth Fund, structured as 170 billion won of convertible bonds and 330 billion won of convertible preferred shares via third-party allotment, with participants including the Korea Development Bank, largest shareholder Pan Orion and a third financial investor; it was reported as the fund's first direct investment in a listed company and in a biopharmaceutical new drug developer. In August 2026, US partner NextCure exited the LNCB74 co-development program ahead of its planned reverse merger with Avere Therapeutics, leaving LigaChem with sole development authority over the B7-H4 ADC while NextCure remains eligible for future milestones and royalties. Other recent items include a 100% ORR/CR readout for LCB71 in first-line DLBCL combination therapy, US FDA Fast Track designation for partner SOTIO's SOT106, approval of a global Phase 1/2 IND for LCB02A, and the appointment of a former Merck (MSD) expert, Dr. Jin-hwa, to a leadership role.
▸Full profile — market position, technology, go-to-market, geography, history, risks & controversies
Market position
LigaChem is one of the more prominent Korean ADC developers, with multiple global licensing and technology transfer deals and a stated goal of becoming a global top ADC company by 2030. In the B7-H4 ADC field it is described as the sole developer of a clinical-stage candidate without a topoisomerase I payload, while competing programs, including Pfizer/Seagen's felmetatug vedotin, use different linker chemistry.
The company positions its ADC platform as overcoming limitations of conventional conjugation chemistry, citing homogeneous DAR, tumor-enriched enzymatic linker cleavage versus more broadly cleaved protease-sensitive linkers such as valine-citrulline chemistry, and improved plasma stability. Its LNCB74 program is described as the only B7-H4-directed ADC in clinical development that does not use a topoisomerase I inhibitor payload, instead using the tubulin-disrupting agent MMAE, giving it a resistance profile that does not overlap with topo I-based ADCs.
Technology
LigaChem's core technology is the ConjuAll ADC platform, which combines site-specific antibody conjugation to an engineered cysteine on the antibody light chain to yield a homogeneous drug-to-antibody ratio of 4, and a linker cleaved specifically by beta-glucuronidase (GUSB), an enzyme abundant in lysosomes and overexpressed in the tumor interstitium, so that payload release is preferentially triggered in tumor cells or the tumor microenvironment. The beta-glucuronide group's hydrophilicity stabilizes lipophilic payloads such as monomethyl auristatin E (MMAE) and limits ADC aggregation, and an Fc-mitigating mutation reduces uptake by Fc receptor-expressing immune cells. The platform spans linkers, PBD toxins and conjugation chemistry, and the company is extending it to novel mechanism-of-action toxins, immuno-oncology payloads, bispecific antibodies and linkers for non-cancer indications.
Go-to-market
Development is advanced through partnerships involving joint research, co-development and licensing with global partners, including Janssen (TROP2 ADC LCB84), SOTIO Biotech, ABL Bio, Ono Pharmaceutical, Samsung Biologics and, previously, NextCure. The company also runs internal clinical programs and investor relations activities such as a Global R&D Day and quarterly results presentations.
Patients with cancers of high unmet medical need are the end beneficiaries; commercially, the company's counterparties are global pharmaceutical and biotech companies that license or co-develop its ADC platform and drug candidates.
Geography
Headquarters and research operations are in Daejeon, Republic of Korea (10, Gukjegwahak 10-ro, Yuseong-gu), with a pharmaceutical sales office in Mapo-gu, Seoul. Development partnerships and clinical activity extend internationally, including US-partnered programs and planned global clinical trials.
History
The company was founded in 2006 as LegoChem Biosciences and changed its name to LigaChem Biosciences at its 18th annual shareholders' meeting on March 29, 2024, 18 years after founding. In January of that year, confectionery group Orion participated in a third-party allotment capital increase, receiving 7,963,283 new shares, and agreed to purchase 1.4 million existing shares from founders Kim Yong-Joo and CEO Park Se-Jin; Orion completed payment of 548.5 billion won ($407 million) for a 25.37% stake on March 29, becoming the largest shareholder, with several Orion executives joining the board. In June 2026 the company secured 500 billion won in direct investment from Korea's National Growth Fund.
Risks & controversies
The company's programs depend on partners, and partner decisions can alter development plans: NextCure ended its cost- and rights-sharing co-development of LNCB74 in August 2026 for capital-preservation reasons tied to its own merger, transferring full development responsibility and cost to LigaChem. Broader risks include clinical-stage development uncertainty and, as noted in coverage of the B7-H4 field, competitive and sequencing dynamics among ADCs using different payload classes.
Compiled by commissioned research from 8 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Timeline · 11
launches, deals, and filingsThe company reported that LCB71, a ROR1-targeting ADC, achieved 100 percent objective response and complete response rates in a first-line diffuse large B-cell lymphoma combination study; related coverage cites 31 first-line DLBCL patients.
SOT106, from LigaChem partner SOTIO, was granted Fast Track designation by the US FDA.
US partner NextCure elected to exit the LNCB74 co-development program to preserve capital ahead of its planned reverse merger with Avere Therapeutics, as disclosed in an SEC Form 8-K filed August 6, 2026. The two companies had co-developed the clinical-stage B7-H4-targeting ADC since November 2022 under a Research Collaboration and Co-Development Agreement with equally shared costs and rights. NextCure remains eligible for future development, regulatory and commercial milestone payments and royalties.
The company raised a total of 500 billion won from the government-led National Growth Fund, consisting of 170 billion won in convertible bonds and 330 billion won in convertible preferred shares, issued via third-party allotment. Participants included the Korea Development Bank (manager of the Advanced Strategic Industry Fund), largest shareholder Pan Orion (an Orion Hong Kong affiliate) and a third financial investor. It was reported as the fund's first direct investment in a listed company and the first in a biopharmaceutical new drug company; combined with existing cash the company said it held cash in the 900 billion won range.
LigaChemBio announced it would receive a milestone payment from SOTIO Biotech.
The company announced the appointment of Dr. Jin-hwa, previously an expert at Merck (MSD).
An IND for a global Phase 1/2 trial of LCB02A, a Claudin 18.2-targeting ADC, was approved; the company targeted entry into global clinical trials in the third quarter of 2026.
At its 18th annual general shareholders' meeting at the Daejeon headquarters, shareholders approved changing the company name from LegoChem Bioscience to LigaChem Bioscience, 18 years after its 2006 founding. Directors were also appointed, with CEO Kim Yong-joo and President Park Se-jin reappointed as inside directors.
Orion announced completion of payment of 548.5 billion won ($407 million) to acquire a 25.37 percent stake, comprising 7,963,283 new shares from a January third-party allotment capital increase and 1.4 million existing shares purchased from founders Kim Yong-Joo and CEO Park Se-Jin, for a total of 9,363,283 shares. Several Orion executives joined the board.
$407M source ↗
LigaChem and NextCure began co-developing the B7-H4-targeted ADC LNCB74 under a Research Collaboration and Co-Development Agreement in which both sides equally shared development costs and rights.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
▸Research sources · 8
primary sources listed
- Ligachembioligachembio.com · web
8 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Ligachembio do?
- Korean clinical-stage biopharmaceutical company developing antibody-drug conjugates and small-molecule oncology therapeutics.
- Who are Ligachembio's investors?
- Ligachembio's investors include Atinum Investment Co. Ltd..